AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NRx Pharmaceuticals Reschedules Q2 2025 Financial Results Release to August 19, 2025
ByAinvest
Wednesday, Aug 13, 2025 6:11 pm ET1min read
NRx Pharmaceuticals reschedules its Q2 2025 financial results release to August 19, 2025, with a conference call on August 20, 2025. The company requires additional time to compile information into the Form 10-Q, including recent developments. The conference call will be available on the company's website, and participants can dial in domestically or internationally to join.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has announced a delay in the release of its second quarter 2025 financial results. The company has rescheduled the release to August 19, 2025, after the market close, with a subsequent conference call scheduled for August 20, 2025, at 8:00 AM ET [2].The rescheduling is due to the need for additional time to compile certain information and recent developments into the Form 10-Q filing. Investors can access the results via a press release on the company's website and join the conference call through a webcast or by dialing +1-800-717-1738 (domestically) or +1-646-307-1865 (internationally) [2].
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 and NRX-101 receiving Fast Track and Breakthrough Therapy Designations, respectively [1].
References:
[1] https://www.biospace.com/press-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-2025-financial-results-on-august-14-2025
[2] https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-inc-nasdaq-nrxp-reschedules-second-quarter-2025-rspkrmpuj7cv.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet